Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643058 · ClinicalTrials.gov registry record · Phase 1
Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II
A Phase 1 study, sponsored by John Sundy.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00643058: Clinical Trial Phase 1 study, sponsored by John Sundy.
NCT00643058 is a Phase 1 study that was terminated before completion, run by John Sundy. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00643058, a Phase 1 study, was terminated before completion, sponsored by John Sundy.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the role of nitric oxide (NO) in asthma and to characterize the symptoms associated with inhaled endotoxin (lipopolysaccharide \[LPS\]) in normal subjects. In this study, we will determine the effect of inhaled endotoxin on exhaled NO in healthy African Americans, with and without NOS2 promoter polymorphisms. The protocol described in this submission will involve the use of NIH Clinical Center Reference Endotoxin which has been approved by the FDA under IND BB-IND-10035.
Interventions
- BIOLOGICAL LPS endotoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2003-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00643058
The ClinicalTrials.gov registry entry for NCT00643058 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Sundy, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LPS endotoxin is the first listed.
NCT00643058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00643058 about?
NCT00643058 is a clinical study titled "Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II". The purpose of the study is to determine the role of nitric oxide (NO) in asthma and to characterize the symptoms associated with inhaled endotoxin (lipopolysaccharide \[LPS\]) in normal subjects. In this study, we will determine the effect of inhaled endotoxin on exhaled NO in healthy African Ameri...
What is the current status of trial NCT00643058?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2003-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00643058?
The interventions under investigation include: LPS endotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00643058?
This trial is sponsored by John Sundy, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.